Mapp Biopharmaceutical

Mapp Biopharmaceutical
Headquarters
San Diego Edit this on Wikidata
,
United States Edit this on Wikidata
Key people
Larry Zeitlin
(President)
Kevin Whaley
(CEO)[1]
ProductsBiopharmaceuticals
SubsidiariesLeafBio
Websitemappbio.com Edit this on Wikidata

Mapp Biopharmaceutical is an American pharmaceutical company founded in 2003 by Larry Zeitlin and Kevin Whaley.[2] Mapp Biopharmaceutical is based in San Diego, California. It is responsible for the research and development of ZMapp, a drug which is still[when?] under development and comprises three humanized monoclonal antibodies used as a treatment for Ebola virus disease.[3][4] The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak.

The ZMapp drug is a result of the collaboration between Mapp Biopharmaceutical, LeafBio (the commercial arm of Mapp Biopharmaceutical),[5] Defyrus Inc. (Toronto), the U.S. government, and the Public Health Agency of Canada.[3] The antibody work came out of research projects funded by Defense Advanced Research Projects Agency (DARPA) more than a decade ago,[1] and years of funding by the Public Health Agency of Canada.[6] ZMapp is manufactured in the tobacco plant Nicotiana benthamiana in the bioproduction process known as "pharming" by Kentucky BioProcessing, a subsidiary of Reynolds American.[7][8][9]

References

[edit]
  1. ^ a b Langreth, Robert; Chen, Caroline; Nash, James; Lauerman, John (August 4, 2014). "Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers". Bloomberg.
  2. ^ "BioPharm Company Tackles "Neglected" Infectious Diseases". Small Business Innovation Research. National Institutes of Health. January 31, 2020. Archived from the original on 20 October 2021. Retrieved 20 October 2021.
  3. ^ a b "ZMapp Information Sheet" (PDF). Mapp Biopharmaceutical. Archived from the original (PDF) on 2014-08-12.
  4. ^ "Mystery Ebola virus serum manufactured by San Diego firm". Los Angeles Times. August 4, 2014.
  5. ^ "LeafBio". Archived from the original on October 8, 2014. Retrieved August 12, 2014.
  6. ^ Helen Branswell for The Canadian Press. Aug. 5, 2014 Experimental Ebola drug based on research discoveries from Canada's national lab
  7. ^ Kroll, David (5 August 2014). "Ebola 'Secret Serum': Small Biopharma, The Army, And Big Tobacco". Forbes.
  8. ^ Parshley, Lois (8 August 2014). "ZMapp: The Experimental Ebola Treatment Explained". Popular Science.
  9. ^ Daniel, Fran (12 August 2014). "Ebola drug provided for two Americans by Reynolds American subsidiary". Winston-Salem Journal.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mapp_Biopharmaceutical&oldid=1210982430"